The World's First Tooth-Regrowth Drug Is Entering Phase II Human Trials

The dentist's chair has long been a place of mechanical repair—drills, synthetic resins, titanium screws, and porcelain crowns. But a quiet revolution in a Japanese laboratory is threatening to render much of that hardware obsolete.[6]

Toregem BioPharma, a biotech spin-out from Kyoto University, recently secured $5.3 million in Pre-Series C funding to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials.[2][3]

The promise is staggering: an intravenous antibody treatment designed to stimulate the human body to grow a brand-new, natural tooth. If successful, it would mark the first time in medical history that a drug has successfully regenerated a human organ structure from dormant tissue.[1][4]

To understand how TRG035 works, one must first understand why humans stop growing teeth. We naturally develop two sets: primary deciduous teeth and permanent adult teeth. For decades, scientists assumed that once the adult teeth erupted, the biological machinery for tooth generation permanently shut down.[6]

However, researchers led by Dr. Katsu Takahashi discovered that humans actually retain vestigial "tooth buds"—the embryonic precursors to a potential third set of teeth. These buds remain dormant because the body actively suppresses them.[1][4]

The molecular brake responsible for this suppression is a protein called Uterine Sensitization Associated Gene-1, or USAG-1. USAG-1 acts as an antagonist to Bone Morphogenetic Protein (BMP) and Wnt signaling pathways, both of which are critical for tissue and bone development.[5]

By binding to these pathways, USAG-1 effectively tells the dormant tooth buds to stay asleep. Takahashi's team realized that if they could neutralize USAG-1, they might be able to release the brake and allow the third dentition to grow.[4][5]

This hypothesis led to the development of TRG035, a monoclonal antibody specifically engineered to block the USAG-1 protein. In a landmark 2021 study published in Science Advances, the researchers demonstrated that administering this antibody to mice and ferrets with congenital tooth agenesis resulted in the growth of fully functional, properly aligned new teeth.[5]

The success in ferrets was particularly encouraging because, unlike mice, ferrets share a similar dental pattern to humans, including the transition from deciduous to permanent teeth. The animals grew new teeth complete with enamel, dentin, and proper biological integration into the jawbone.[5]

Moving from animal models to humans, Toregem BioPharma initiated Phase I clinical trials at Kyoto University Hospital in late 2024. The trial enrolled 30 healthy adult men, aged 30 to 64, who were missing at least one molar.[3][4]

The primary goal of Phase I was strictly to evaluate the drug's safety and tolerability in humans, not to measure tooth regrowth. According to the company, the initial safety trials concluded without any serious adverse events, clearing the path for the next crucial phase of testing.[1][4]

With the newly raised $5.3 million, Toregem is now preparing for Phase II trials, which will target a highly specific and vulnerable demographic: children aged 2 to 7 who suffer from severe congenital hypodontia.[1][3]

Congenital hypodontia is a genetic condition characterized by the absence of six or more permanent teeth. For these pediatric patients, the clinical stakes are immense. Because titanium implants cannot be safely placed in a child's growing jawbone, these patients are often forced to rely on removable dentures for years.[1]

This reliance on prosthetics during crucial developmental years can lead to severe complications with chewing, nutrition, speech development, and overall quality of life. If TRG035 can successfully induce tooth growth in these children, it would offer a life-altering biological cure rather than a mechanical stopgap.[1]

While the pediatric trials are the immediate focus, Toregem's ultimate vision extends much further. The company hopes to eventually offer the drug to adults who have lost teeth due to severe decay, gum disease, or traumatic injury.[2][4]

The timeline for such widespread availability remains ambitious. Researchers are targeting regulatory approval and commercial release by the year 2030. However, experts caution that the leap from animal efficacy to human efficacy is notoriously difficult in drug development.[2][4]

One of the primary biological hurdles is ensuring that the regenerated tooth grows in the correct location, achieves the right size, and aligns properly with the surrounding dentition. The body's signaling pathways are highly complex, and manipulating them requires immense precision.[5][6]

Furthermore, some dental researchers have expressed skepticism about whether the treatment will be as effective in older adults as it might be in children. Children possess a higher density of dental epithelial cells, which play a foundational role in tooth development, whereas adults may lack the necessary cellular environment to support robust regrowth.[2]

Despite these uncertainties, the progress of TRG035 represents a paradigm shift in medical science. Dentistry is on the precipice of moving beyond the era of fillings and extractions, inching closer to a future where a missing tooth is treated not with a drill, but with a biological cue to heal.[4][6]